• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Carmell Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    3/5/25 5:00:08 PM ET
    $CTCX
    Medical/Dental Instruments
    Health Care
    Get the next $CTCX alert in real time by email
    8-K
    false0001842939Longevity Health Holdings, Inc.0001842939us-gaap:CommonStockMember2025-03-042025-03-040001842939us-gaap:WarrantMember2025-03-042025-03-0400018429392025-03-042025-03-04

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): March 04, 2025

     

     

    Carmell Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40228

    86-1645738

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2403 Sidney Street, Suite 300

     

    Pittsburgh, Pennsylvania

     

    15203

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 412 894-8248

     

     

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    CTCX

     

    The Nasdaq Stock Market LLC

    Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

     

    CTCXW

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

    As previously disclosed, on August 30, 2024, Carmell Corporation, a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department (the “Department”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, from July 15, 2024 to August 29, 2024, the Company’s Market Value of Listed Securities (the “MVLS”) was below the minimum of $35 million required for continued listing on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(2) (the “MVLS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq provided the Company with 180 calendar days, or until February 26, 2025 (the “Compliance Date”), to regain compliance with the MVLS Requirement.

    On March 4, 2025, the Company received written notice from the Department notifying the Company that it had failed to regain compliance with the MVLS Requirement by the Compliance Date. As such, unless the Company requests an appeal of Nasdaq’s determination to delist the Company’s securities from the Nasdaq Capital Market by March 11, 2025, trading of the Company’s common stock will be suspended at the opening of business on March 13, 2025, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on Nasdaq.

    The Company intends to appeal Nasdaq’s decision, but no guarantee can be provided that it will be successful in doing so and that its securities will continue to be listed on the Nasdaq Capital Market. A request for an appeal will stay the delisting of the Company’s securities pending Nasdaq’s decision.

    Forward-Looking Statements

    This Current Report contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes that it has a reasonable basis for each forward-looking statement contained in this Current Report, the Company cautions you that these statements are based on a combination of facts and factors currently known by it and its projections of the future, about which the Company cannot be certain. Forward-looking statements in this Current Report include, but are not limited to, statements regarding the Company’s ability to regain compliance with the MVLS Requirement and the Company’s ability to appeal Nasdaq’s decision to delist the Company’s securities. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by the Company with the SEC on April 1, 2024, and in the Company’s other reports filed with the SEC. Most of these factors are outside of the Company’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this Current Report.

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    CARMELL CORPORATION

     

     

     

     

    Date:

    March 5, 2025

    By:

    /s/ Bryan J. Cassaday

     

     

     

    Chief Financial Officer

     


    Get the next $CTCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CTCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

      Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

      3/10/25 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Announces Closing of Elevai Skincare Acquisition

      PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. ("Elevai"), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) ("PMGC") and Elevai, its wholly owned subsidiary (the "Acquisition"). At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 mill

      1/16/25 8:00:28 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out

      PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The Private Placement was priced at a slight premium t

      1/3/25 8:00:03 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    SEC Filings

    See more
    • SEC Form 424B3 filed by Carmell Corporation

      424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/26/25 5:01:17 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/26/25 5:00:09 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Carmell Corporation

      424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/10/25 8:53:40 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Carmell Corporation

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      12/6/24 4:16:05 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Carmell Corporation

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      11/14/24 2:48:40 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Carmell Corporation (Amendment)

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      4/18/24 3:03:07 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Upton Richard A bought $2,336 worth of shares (5,000 units at $0.47), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/16/24 4:30:07 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Director Frisch Scott M. bought $515 worth of shares (1,009 units at $0.51) (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/10/24 4:30:11 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Director Gregory Kathryn bought $643 worth of shares (1,260 units at $0.51) (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/10/24 4:30:16 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Bracken-Ferguson Kendra

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:13:51 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Gregory Kathryn

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:00:05 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cassaday Bryan J.

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:00:12 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Leadership Updates

    Live Leadership Updates

    See more
    • CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

      Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

      3/10/25 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

      PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi

      7/29/24 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

      PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co

      3/20/24 4:39:36 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care